Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Inovio Pharmaceuticals
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic Hepatitis B virus infection
Negative for Hepatitis A IgM, C, D and HIV
Liver biopsy, Fibroscan® or equivalent elastography-based test obtained within the past 6 months demonstrating liver disease without evidence of bridging fibrosis or cirrhosis supported by platelet count greater than the central laboratory LLN at screening
Positive for Hepatitis B surface antigen (≥250 IU/mL at screening)
Nucleos(t)ide treatment for at least 1 year with ongoing nucleos(t)ide analogue treatment at randomization
HBV DNA \<90 IU/mL for ≥6 months prior to randomization
Screening laboratory values within normal range
ALT ≤1.5x upper limit of normal (ULN) from 2 measurements separated by at least 14 days during the 6 months prior to randomization and ALT at screening ≤1.5x ULN
AST, TBili, DBili, GGT, Alk Phos and albumin within normal range or judged to be not clinically significant by PI and medical monitor at screening
For men and women who are not postmenopausal \[i.e. ≥ 12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone (FSH), if not on hormone replacement\] or surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females) agreement to remain abstinent or use 1 highly effective or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and at least through week 12 after last dose
You may not be if
Pregnant or breastfeeding females
Positive serum pregnancy test at screening or positive urine pregnancy test at randomization
Use of topical corticosteroids at or near the intended administration site
Autoimmune disorders, transplant recipients, other immunosuppression including any concurrent condition requiring the use of immunosuppressive/immunomodulating agents (eye drop-containing and infrequent inhaled corticosteroids are permissible)
Need for systemic antiviral treatment (other than for chronic hepatitis B infection)
Documented history or other evidence of decompensated liver disease (e.g., ascites, bleeding from esophageal varices, Child-Pugh clinical classification B or C)
History of liver cirrhosis demonstrated by biopsy, Fibroscan® or equivalent elastography-based test
History of other evidence of a medical condition associated with chronic liver disease \[e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), toxin exposure, thalassemia, etc.\]
Documented history or other evidence of metabolic liver disease within 1yr of randomization
Abnormal renal function including serum creatinine \>ULN or calculated creatinine clearance \<70 mL/min (using the Cockcroft Gault formula)
History of or suspicion of HCC
Screening alpha fetoprotein ≥13 ng/mL
Prior history or current malignancy other than adequately treated BCC, unless history of BCC is near intended administration site
History of significant medical conditions \[e.g., cardiac (including ventricular or supraventricular arrhythmias), renal disease, pulmonary, gastrointestinal, neurological\]
Significant acute infection (e.g., influenza, local infection) or any other clinically significant illness within 2 weeks of randomization
Administration of any blood product within 3 mon of randomization
History of seizures (unless seizure free for 5yrs)